amlodipine has been researched along with Cardiovascular Diseases in 190 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a pragmatic comparative effectiveness study carried out at 110 centers across China in outpatients with primary hypertension treated with levoamlodipine maleate or amlodipine besylate, with 24 months of follow-up." | 9.41 | Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study. ( Chen, P; Cui, L; Cui, W; Dang, A; Dong, Y; Du, X; Duan, C; Gao, P; Hua, Q; Huo, Y; Jiang, Y; Li, J; Ma, W; Qi, X; Qu, P; Sun, N; Sun, Y; Wu, G; Xie, J; Zhao, L, 2021) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 9.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide." | 9.13 | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. ( Bakris, GL; Dahlöf, B; Gatlin, M; Gupte, J; Hester, A; Jamerson, K; Pitt, B; Shi, V; Velazquez, EJ; Weber, MA, 2008) |
| "A systematic literature search is undertaken for supporting the pharmacological proprieties and clinical efficacy of perindopril in the treatment of hypertension." | 8.87 | Perindopril for the treatment of hypertension. ( Ghiadoni, L, 2011) |
| "Single-pill amlodipine besylate/atorvastatin calcium (Caduet), Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia (DYS)." | 8.82 | Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. ( Cowie, MR, 2005) |
| "This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors." | 8.31 | Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. ( Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023) |
| "Amlodipine, calcium channel blocker (CCB), is used in the management of cardiovascular diseases which causes gingival overgrowth (GO)." | 7.96 | The gingival crevicular fluid levels of growth factors in patients with amlodipine-induced gingival overgrowth: A pilot study. ( Agrali, OB; Kose, KN; Kuru, B; Kuru, L; Noyan, U; Ozener, HO; Yildirim, HS; Yilmaz, S, 2020) |
| "amlodipine, is a milestone in the effort to test whether newer compounds offer a better reduction of the cardiovascular consequences of hypertension, as well as good BP control." | 7.79 | Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. ( Julius, S, 1999) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 6.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| " Of all ongoing mortality and morbidity trials in systemic hypertension, VALUE (Valsartan Antihypertensive Long-term Use Evaluation) is the only one comparing an angiotensin II antagonist (valsartan) with a third-generation calcium channel blocker (amlodipine)." | 6.69 | The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. ( Julius, S; Mann, J, 1998) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 6.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| " The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets." | 6.46 | Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010) |
| "There is lacking evidence that telmisartan can improve insulin resistance in patients on high-intensity statins." | 5.51 | Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial. ( Kang, TS; Kim, BK; Kim, JY; Lee, CJ; Lee, SH; Park, S; Sung, JH, 2022) |
| "This was a pragmatic comparative effectiveness study carried out at 110 centers across China in outpatients with primary hypertension treated with levoamlodipine maleate or amlodipine besylate, with 24 months of follow-up." | 5.41 | Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study. ( Chen, P; Cui, L; Cui, W; Dang, A; Dong, Y; Du, X; Duan, C; Gao, P; Hua, Q; Huo, Y; Jiang, Y; Li, J; Ma, W; Qi, X; Qu, P; Sun, N; Sun, Y; Wu, G; Xie, J; Zhao, L, 2021) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 5.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "In this study, which titrated medications to a goal, participants assigned to chlorthalidone were less likely to develop treatment-resistant hypertension." | 5.24 | Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. ( Bangalore, S; Black, HR; Calhoun, DA; Cushman, WC; Davis, BR; Kostis, JB; Muntner, PM; Pressel, SL; Probstfield, JL; Rahman, M; Whelton, PK, 2017) |
| "213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B)." | 5.20 | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2015) |
| " We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m(2); normal weight (BMI <25), overweight (BMI = 25-29." | 5.19 | Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. ( Barzilay, JI; Dart, RA; Davis, BR; Einhorn, PT; Graves, JW; Pressel, SL; Reisin, E; Retta, TM; Saklayen, MG; Yamal, JM, 2014) |
| "Single-pill amlodipine/atorvastatin was associated with significant improvements in BP, LDL-C target attainment, and 10-year CV risk in patients with uncontrolled hypertension in Slovakia." | 5.17 | Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study). ( Fedacko, J; Janicko, M; Jarcuska, P; Jedlickova, L; Kmec, J; Lopuchovsky, T; Merkovska, L; Pella, D; Sabol, F; Sajty, M, 2013) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 5.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| " In this study, we investigated the effects of valsartan and amlodipine on the lipid profile in patients with newly diagnosed essential hypertension." | 5.17 | An additional LDL-lowering effect of amlodipine; not only an antihypertensive? ( Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H, 2013) |
| " Therefore, we designed a randomized controlled trial using amlodipine as the base drug of a multi-drug regimen, the Optimal Combination of Effective ANtihypertensives (OCEAN) Study, to determine the drug combination that is most efficacious in the prevention of cardiovascular events, such as stroke." | 5.16 | Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in Japan. ( Kageyama, S; Miyakawa, M; Mochizuki, K; Nakayama, M; Ohashi, Y; Saito, I; Saruta, T; Sugawara, M; Ueda, S, 2012) |
| "The ACCOMPLISH trial (Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension) was a 3-year multicenter, event-driven trial involving patients with high cardiovascular risk who were randomized in a double-blinded manner to benazepril plus either hydrochlorothiazide or amlodipine and titrated in parallel to reach recommended blood pressure goals." | 5.16 | Renal outcomes in hypertensive Black patients at high cardiovascular risk. ( Bakris, GL; Dahlof, B; Devereux, RB; Hester, RA; Hua, TA; Jamerson, KA; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, E; Weber, MA; Weir, MR; Wright, JT, 2012) |
| "The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients." | 5.15 | The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. ( Deng, Q; Liu, L; Liu, M; Ma, L; Wang, W; Zhang, Y, 2011) |
| "The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia." | 5.14 | Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). ( Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF, 2009) |
| "Single-pill amlodipine/atorvastatin targets the two most common modifiable cardiovascular risk factors, hypertension and dyslipidaemia." | 5.14 | International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. ( Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD, 2009) |
| "The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| "In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide." | 5.13 | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. ( Bakris, GL; Dahlöf, B; Gatlin, M; Gupte, J; Hester, A; Jamerson, K; Pitt, B; Shi, V; Velazquez, EJ; Weber, MA, 2008) |
| "The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen." | 5.13 | The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. ( Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| "15?245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine." | 5.11 | Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. ( Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, J; McInnes, GT; Mitchell, L; Plat, F; Schork, A; Smith, B; Weber, M; Zanchetti, A, 2004) |
| "To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril." | 5.09 | Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. ( , 2000) |
| "A systematic literature search is undertaken for supporting the pharmacological proprieties and clinical efficacy of perindopril in the treatment of hypertension." | 4.87 | Perindopril for the treatment of hypertension. ( Ghiadoni, L, 2011) |
| "Single-pill amlodipine besylate/atorvastatin calcium (Caduet), Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia (DYS)." | 4.82 | Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. ( Cowie, MR, 2005) |
| "This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors." | 4.31 | Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. ( Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023) |
| "Amlodipine, calcium channel blocker (CCB), is used in the management of cardiovascular diseases which causes gingival overgrowth (GO)." | 3.96 | The gingival crevicular fluid levels of growth factors in patients with amlodipine-induced gingival overgrowth: A pilot study. ( Agrali, OB; Kose, KN; Kuru, B; Kuru, L; Noyan, U; Ozener, HO; Yildirim, HS; Yilmaz, S, 2020) |
| "During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan." | 3.88 | Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. ( Ichihara, C; Kitao, H; Konda, M; Kuwabara, Y; Liu, J; Oba, K; Ueshima, K; Yasuno, S, 2018) |
| " The fixed combination of rosuvastatin with ACE inhibitor lisinopril and calcium antagonist amlodipine allows to control effectively two main cardiovascular risk factors: hypercholesterolemia and arterial hypertension." | 3.85 | [Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease]. ( Semenova, AE; Sergienko, IV, 2017) |
| "Hypertension is a highly prevalent disease and a strong risk factor for cardiovascular disease in industrialized countries in Europe and North America." | 3.83 | [Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. ( Kékes, E, 2008) |
| "This retrospective claims database analysis compared two strategies of hypertension treatment in outpatient, emergency, and inpatient departments: a fixed-dose combination (FDC) of amlodipine/valsartan vs free combinations of angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) (ARB+CCB group)." | 3.81 | Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. ( Chang, CJ; Chu, PH; Lin, YS; Tung, YC; Wu, LS, 2015) |
| "amlodipine, is a milestone in the effort to test whether newer compounds offer a better reduction of the cardiovascular consequences of hypertension, as well as good BP control." | 3.79 | Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. ( Julius, S, 1999) |
| "A prospective (90 days), multicenter, multilevel pharmacoepidemiologic study was conducted in 3546 patients with hypertension treated with SPC amlodipine/valsartan by 698 general practitioners." | 3.77 | Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study). ( Abraham, I; Aerts, A; Brié, H; Coen, N; Hermans, C; Lee, C; Lins, R; MacDonald, K; Mecum, N; Shen, YM; Vancayzeele, S, 2011) |
| "To assess the cost effectiveness of four alternative treatment strategies in patients with hypertension and three or more cardiovascular risk factors in the UK (from the UK NHS perspective) or Sweden (from the societal perspective): amlodipine-based plus atorvastatin, atenolol-based plus atorvastatin, amlodipine-based alone and atenolol-based alone." | 3.75 | The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| " The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial compares regimens of benazepril plus amlodipine versus benazepril plus hydrochlorothiazide, force-titrated to 40/10 and 40/25mg, respectively." | 3.73 | The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies. ( Weder, AB, 2005) |
| "The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on valsartan or amlodipine would have differing effects on cardiovascular endpoints in high risk hypertension." | 3.72 | Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. ( Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, JH; McInnes, GT; Mitchell, L; Plat, F; Schork, MA; Smith, B; Weber, MA; Zanchetti, A, 2004) |
| " In the absence of AH, patients received scheme I -(Mertenil® at initial dosage of 10 mg/day)." | 2.90 | ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk. ( Ansheles, AA; Boytsov, SA; Drapkina, ОМ; Gornyakova, NB; Kuharchuk, VV; Sergienko, IV; Shepel, RN; Zubareva, MY, 2019) |
| "Although orthostatic hypotension (OH) is often considered a contraindication to blood pressure (BP) treatment, evidence is lacking." | 2.87 | Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease. ( Appel, LJ; Juraschek, SP; Lipsitz, LA; Miller, ER; Mukamal, KJ, 2018) |
| " The case for fixed-dose combination (FDC) oral dosage forms and orally disintegrating tablet (ODT) technology to enhance outcomes and compliance is strong." | 2.84 | Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. ( Badhan, RK; Dennison, TJ; Mohammed, AR; Smith, JC, 2017) |
| "Treatment with amlodipine, however, was not associated with a significant difference in conduction outcome events (HR, 0." | 2.82 | Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. ( Albert, CM; Alonso, A; Davis, BR; Dewland, TA; Haywood, LJ; Magnani, JW; Marcus, GM; Piller, LB; Soliman, EZ; Yamal, JM, 2016) |
| "The primary composite outcomes were sudden cardiac death, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure." | 2.78 | Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. ( Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K, 2013) |
| "Hyperkalemia was associated with increased risk of combined cardiovascular disease (hazard ratio, 1." | 2.77 | Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. ( Alderman, MH; Calhoun, DA; Cushman, WC; Davis, BR; Eckfeldt, JH; Einhorn, PT; Ford, CE; Franklin, SS; Furberg, CD; Ong, ST; Oparil, S; Papademetriou, V; Piller, LB; Probstfield, JL, 2012) |
| "Antihypertensive therapy is effective in reducing the risk of major adverse cardiovascular events." | 2.77 | Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. ( Deng, Q; Liu, L; Liu, M; Ma, L; Sun, H; Wang, J; Wang, W; Zhang, Y; Zhao, Y, 2012) |
"Eligible patients had treated or untreated hypertension, >or=3 additional cardiovascular risk factors, and baseline total cholesterol| 2.75 | Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. ( Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J, 2010) | |
| "Amlodipine-based treatment was associated with a smaller arteriolar length:diameter ratio than atenolol-based treatment (13." | 2.74 | Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy. ( Allemann, S; Chaturvedi, N; Hughes, A; Mayet, J; O'Brien, E; Poulter, N; Sever, P; Stanton, A; Stettler, C; Tapp, R; Thom, S; Witt, N, 2009) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 2.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Angioedema is a rare, potentially life-threatening condition that has been associated with angiotensin-converting enzyme inhibitors since their introduction in the 1980s." | 2.72 | Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Black, HR; Davis, BR; Ford, CE; Nwachuku, C; Oparil, S; Piller, LB; Probstfield, JL; Retta, TM, 2006) |
| "The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause." | 2.71 | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003) |
| "The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study compares cardiovascular outcomes in 15,314 eligible patients from 31 countries randomized to valsartan or amlodipine-based treatment." | 2.71 | VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. ( Brunner, H; Ekman, S; Hansson, L; Julius, S; Kjeldsen, SE; Laragh, JH; McInnes, G; Platt, F; Schork, AM; Smith, B; Weber, M; Zanchetti, A, 2003) |
| " Of all ongoing mortality and morbidity trials in systemic hypertension, VALUE (Valsartan Antihypertensive Long-term Use Evaluation) is the only one comparing an angiotensin II antagonist (valsartan) with a third-generation calcium channel blocker (amlodipine)." | 2.69 | The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. ( Julius, S; Mann, J, 1998) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 2.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| " The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets." | 2.46 | Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010) |
| " Although the overall goal of these drugs remains the blockade of RAS activation, their individual targets in this system vary and may substantially influence the clinical benefit derived from the long term use of these substances." | 2.45 | Angiotensin II type 1 receptor blockade: high hopes sent back to reality? ( Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B, 2009) |
| "Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition." | 2.45 | Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. ( Bangalore, S; Devabhaktuni, M, 2009) |
| " In particular, reduced bioavailability of endothelial-dependent nitric oxide production as a result of enhanced oxidative stress represents a common pathological mechanism of cardiovascular risk factors." | 2.44 | Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management. ( Mason, RP, 2008) |
| "Atorvastatin has little or no ability to increase high density lipoprotein (HDL)-cholesterol, and this may be a disadvantage in patients with metabolic syndrome or diabetes, where low HDL-cholesterol is a key feature." | 2.43 | Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. ( Doggrell, SA, 2006) |
| " Combination therapy of amlodipine besylate (Norvasc, Pfizer Ltd) with atorvastatin calcium (Lipitor, Pfizer Ltd), marketed as Caduet (Pfizer Ltd) is the first dual-therapy compound designed to treat hypertension and/or angina and dyslipidemia concurrently with a single daily pill in the full range of dosing combinations." | 2.42 | Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. ( Frishman, WH; Zuckerman, AL, 2004) |
| "Amlodipine is a potent peripheral and coronary vasodilator with high selectivity for vascular smooth muscle and minimal effect on myocardial contractility or cardiac conduction." | 2.39 | Amlodipine: a new calcium antagonist. ( Clavijo, GA; de Clavijo, IV; Weart, CW, 1994) |
| " Thus, amlodipine seems to provide a useful alternative to other agents currently available for the treatment of essential hypertension and chronic stable angina pectoris, with certain pharmacodynamic and tolerability properties that should be advantageous in many patients." | 2.38 | Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. ( Heel, RC; Murdoch, D, 1991) |
| ": The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications." | 1.56 | Aging does not impact drug--drug interaction magnitudes with antiretrovirals. ( Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M, 2020) |
| "Atorvastatin treatment of fructose-fed rats increased vascular BH4 content, which was associated with an increase in endothelial NO synthase activity as well as a reduction in endothelial O2(-) production." | 1.40 | Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. ( Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y, 2014) |
| "Olmesartan has been also widely examined in combination of either hydrochlorothiazide or amlodipine, as well as with both drugs in a single-pill triple combination, showing improvements in antihypertensive efficacy without significant effects on tolerability." | 1.39 | Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. ( de la Sierra, A; Volpe, M, 2013) |
| "Cardiovascular diseases are the leading cause of death worldwide." | 1.39 | Fixed combination of amlodipine/atorvastatin: from mechanisms to trials. ( Ivanovic, B; Tadic, M, 2013) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 1.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "Arterial hypertension is an important cardiovascular risk factor." | 1.35 | [Clinical study of the month. The ACCOMPLISH study: challenging the choice of antihypertensive medications in systolic hypertensive patients with high cardiovascular risk]. ( Krzesinski, JM; Scheen, AJ, 2009) |
| "Cardiac complications were defined as left ventricular hypertrophy (LVH) and ischemic heart disease (IHD)." | 1.35 | Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. ( Fujimoto, A; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2009) |
| "Heart failure was two times more prevalent in obese patients." | 1.34 | [Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. ( Aguilar Llopis, A; Arístegui Urrestarazu, R; Armada Peláez, B; Cosín Aguilar, J; Hernándiz Martínez, A; Masramón Morell, X; Rodríguez Padial, L; Zamorano Gómez, JL, 2007) |
| " Damage to the endothelium leads to reduced NO bioavailability and facilitates vessel wall permeability to low-density lipoprotein." | 1.33 | A rationale for combination therapy in risk factor management: a mechanistic perspective. ( Mason, RP, 2005) |
| "It is predicted that future treatment of hypertension will be increasingly tailored to the epidemiologic profiles and medical costs of individual communities." | 1.33 | Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan. ( Ikeda, S; Ikegami, N; Sakamaki, Y; Saruta, T; Sasamura, H, 2006) |
| "Amlodipine was injected intraperitoneally in a dose of 5 mg/kg/day, either once daily at 8." | 1.30 | Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR(mREN2)27 rats. ( Kränzlin, B; Lemmer, B; Schmidt, T; Schnecko, A; Voll, C; Witte, K, 1999) |
| "The incidence of gingival hyperplasia has been reported as 10%-20% in patients treated with calcium antagonists in the general population." | 1.30 | Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients. ( Nakamoto, H; Okada, H; Shouda, J; Sugahara, S; Suzuki, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.53) | 18.7374 |
| 1990's | 17 (8.95) | 18.2507 |
| 2000's | 91 (47.89) | 29.6817 |
| 2010's | 69 (36.32) | 24.3611 |
| 2020's | 12 (6.32) | 2.80 |
| Authors | Studies |
|---|---|
| Itoga, NK | 1 |
| Tawfik, DS | 1 |
| Montez-Rath, ME | 1 |
| Chang, TI | 1 |
| Lee, CJ | 1 |
| Sung, JH | 1 |
| Kang, TS | 1 |
| Park, S | 2 |
| Lee, SH | 1 |
| Kim, JY | 1 |
| Kim, BK | 1 |
| Gallo, G | 1 |
| Sarzani, R | 1 |
| Cicero, AFG | 1 |
| Genovese, S | 1 |
| Pirro, M | 1 |
| Gallelli, L | 1 |
| Faggiano, A | 1 |
| Volpe, M | 2 |
| Oh, J | 1 |
| Kim, W | 1 |
| Kim, GH | 1 |
| Kim, HL | 1 |
| Park, SD | 1 |
| Min, KW | 1 |
| Hyun, D | 1 |
| Hong, JH | 1 |
| Lim, S | 1 |
| Shin, J | 1 |
| Tůmová, E | 1 |
| Vrablík, M | 1 |
| Stader, F | 1 |
| Decosterd, L | 1 |
| Stoeckle, M | 1 |
| Cavassini, M | 1 |
| Battegay, M | 1 |
| Saldanha, SA | 1 |
| Marzolini, C | 1 |
| Courlet, P | 1 |
| Kose, KN | 1 |
| Yilmaz, S | 1 |
| Noyan, U | 1 |
| Kuru, B | 1 |
| Yildirim, HS | 1 |
| Agrali, OB | 1 |
| Ozener, HO | 1 |
| Kuru, L | 1 |
| LeRoy, JM | 1 |
| Boley, SP | 1 |
| Corcoran, JN | 1 |
| Engebretsen, KM | 1 |
| Stellpflug, SJ | 1 |
| Shikh, E | 1 |
| Zozina, V | 1 |
| Kondratenko, S | 1 |
| Melnikov, E | 1 |
| Kukes, V | 1 |
| Ma, W | 1 |
| Sun, N | 1 |
| Duan, C | 1 |
| Zhao, L | 2 |
| Hua, Q | 1 |
| Sun, Y | 1 |
| Dang, A | 1 |
| Gao, P | 1 |
| Qu, P | 1 |
| Cui, W | 1 |
| Dong, Y | 1 |
| Cui, L | 1 |
| Qi, X | 1 |
| Jiang, Y | 1 |
| Xie, J | 1 |
| Li, J | 1 |
| Wu, G | 1 |
| Du, X | 1 |
| Huo, Y | 1 |
| Chen, P | 1 |
| Lancellotti, P | 1 |
| Ancion, A | 1 |
| Scheen, AJ | 2 |
| Macaulay, TE | 1 |
| Sheridan, E | 1 |
| Ward, S | 1 |
| Dennison, TJ | 1 |
| Smith, JC | 1 |
| Badhan, RK | 1 |
| Mohammed, AR | 1 |
| Dhruva, SS | 1 |
| Huang, C | 1 |
| Spatz, ES | 1 |
| Coppi, AC | 1 |
| Warner, F | 1 |
| Li, SX | 1 |
| Lin, H | 1 |
| Xu, X | 1 |
| Furberg, CD | 3 |
| Davis, BR | 14 |
| Pressel, SL | 3 |
| Coifman, RR | 1 |
| Krumholz, HM | 1 |
| Dalal, KS | 1 |
| Bridgeman, MB | 1 |
| Radermecker, RP | 1 |
| Semenova, AE | 1 |
| Sergienko, IV | 2 |
| Liu, J | 1 |
| Yasuno, S | 5 |
| Oba, K | 6 |
| Konda, M | 1 |
| Ichihara, C | 1 |
| Kitao, H | 1 |
| Kuwabara, Y | 3 |
| Ueshima, K | 6 |
| Gupta, A | 1 |
| Mackay, J | 1 |
| Whitehouse, A | 1 |
| Godec, T | 1 |
| Collier, T | 1 |
| Pocock, S | 1 |
| Poulter, N | 2 |
| Sever, P | 2 |
| Ashcroft, JA | 1 |
| Juraschek, SP | 1 |
| Appel, LJ | 1 |
| Miller, ER | 1 |
| Mukamal, KJ | 1 |
| Lipsitz, LA | 1 |
| Pereira, BC | 1 |
| Isreb, A | 1 |
| Forbes, RT | 1 |
| Dores, F | 1 |
| Habashy, R | 1 |
| Petit, JB | 1 |
| Alhnan, MA | 1 |
| Oga, EF | 1 |
| Ansheles, AA | 1 |
| Drapkina, ОМ | 1 |
| Gornyakova, NB | 1 |
| Zubareva, MY | 1 |
| Shepel, RN | 1 |
| Kuharchuk, VV | 1 |
| Boytsov, SA | 1 |
| Athyros, VG | 1 |
| Katsiki, N | 1 |
| Karagiannis, A | 1 |
| Koyanagi, R | 1 |
| Hagiwara, N | 1 |
| Yamaguchi, J | 1 |
| Kawada-Watanabe, E | 1 |
| Haruta, S | 1 |
| Takagi, A | 1 |
| Ogawa, H | 2 |
| Ivanovic, B | 1 |
| Tadic, M | 1 |
| Martsevich, SIu | 1 |
| Kutishenko, NP | 1 |
| Gaĭsenok, OV | 1 |
| Tripkosh, SG | 1 |
| Yamashita, K | 1 |
| Kondo, T | 1 |
| Muramatsu, T | 1 |
| Matsushita, K | 1 |
| Nagahiro, T | 1 |
| Maeda, K | 1 |
| Shintani, S | 1 |
| Murohara, T | 1 |
| Chrysant, SG | 2 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Cutlip, DE | 1 |
| Jamerson, K | 4 |
| Henrich, W | 1 |
| Reid, DM | 1 |
| Cohen, DJ | 1 |
| Matsumoto, AH | 1 |
| Steffes, M | 1 |
| Jaff, MR | 1 |
| Prince, MR | 1 |
| Lewis, EF | 1 |
| Tuttle, KR | 1 |
| Shapiro, JI | 1 |
| Rundback, JH | 1 |
| Massaro, JM | 1 |
| D'Agostino, RB | 1 |
| Dworkin, LD | 1 |
| Okamura, T | 1 |
| Tawa, M | 1 |
| Geddawy, A | 1 |
| Shimosato, T | 1 |
| Iwasaki, H | 1 |
| Shintaku, H | 1 |
| Yoshida, Y | 1 |
| Masada, M | 1 |
| Shinozaki, K | 2 |
| Imamura, T | 1 |
| Wang, JG | 1 |
| Yan, P | 2 |
| Jeffers, BW | 2 |
| Cho, EJ | 1 |
| Kim, JH | 3 |
| Sutradhar, S | 4 |
| Yunis, C | 4 |
| Westergaard, M | 3 |
| Reisin, E | 1 |
| Graves, JW | 1 |
| Yamal, JM | 2 |
| Barzilay, JI | 1 |
| Einhorn, PT | 2 |
| Dart, RA | 1 |
| Retta, TM | 2 |
| Saklayen, MG | 1 |
| Tung, YC | 1 |
| Lin, YS | 1 |
| Wu, LS | 1 |
| Chang, CJ | 1 |
| Chu, PH | 1 |
| Borghi, C | 1 |
| Morbini, M | 1 |
| Cicero, AF | 1 |
| Elliott, WJ | 1 |
| Derosa, G | 2 |
| Mugellini, A | 1 |
| Pesce, RM | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 2 |
| Bertrand, ME | 1 |
| Vlachopoulos, C | 1 |
| Mourad, JJ | 1 |
| Dewland, TA | 1 |
| Soliman, EZ | 1 |
| Magnani, JW | 1 |
| Piller, LB | 3 |
| Haywood, LJ | 3 |
| Alonso, A | 1 |
| Albert, CM | 1 |
| Marcus, GM | 1 |
| Cerezo, C | 1 |
| Degli Esposti, L | 1 |
| Sangiorgi, D | 1 |
| Buda, S | 1 |
| Degli Esposti, E | 1 |
| Scaglione, F | 1 |
| Bangalore, S | 2 |
| Cushman, WC | 5 |
| Muntner, PM | 1 |
| Calhoun, DA | 2 |
| Kostis, JB | 1 |
| Whelton, PK | 4 |
| Probstfield, JL | 4 |
| Rahman, M | 2 |
| Black, HR | 3 |
| Ferket, BS | 1 |
| Hunink, MG | 1 |
| Khanji, M | 1 |
| Agarwal, I | 1 |
| Fleischmann, KE | 1 |
| Petersen, SE | 1 |
| Tepel, M | 1 |
| Hopfenmueller, W | 1 |
| Scholze, A | 1 |
| Maier, A | 1 |
| Zidek, W | 2 |
| Aumiller, J | 1 |
| Mehlsen, J | 2 |
| Erdine, S | 3 |
| Ro, YM | 1 |
| Tse, HF | 1 |
| Howes, LG | 1 |
| Aguilar-Salinas, CA | 1 |
| Chaves, H | 1 |
| Guindy, R | 1 |
| Chopra, P | 1 |
| Moller, RA | 1 |
| Schou, IM | 1 |
| Kékes, E | 1 |
| Fujimoto, A | 4 |
| Sato, T | 3 |
| Fukiyama, K | 4 |
| Azuma, J | 1 |
| Ogihara, T | 7 |
| Saruta, T | 8 |
| Nakao, K | 6 |
| Pimenta, E | 1 |
| Oparil, S | 3 |
| Ostergren, J | 1 |
| Poulter, NR | 2 |
| Sever, PS | 2 |
| Dahlöf, B | 6 |
| Wedel, H | 2 |
| Beevers, G | 1 |
| Caulfield, M | 1 |
| Collins, R | 1 |
| Kjeldsen, SE | 7 |
| Kristinsson, A | 1 |
| McInnes, GT | 5 |
| Nieminen, M | 1 |
| O'Brien, E | 2 |
| Chobanian, AV | 1 |
| Weber, MA | 7 |
| Bakris, GL | 5 |
| Pitt, B | 4 |
| Shi, V | 2 |
| Hester, A | 1 |
| Gupte, J | 1 |
| Gatlin, M | 1 |
| Velazquez, EJ | 3 |
| Escobar, C | 1 |
| Barrios, V | 1 |
| Widimský, J | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Kahan, T | 1 |
| Jönsson, B | 1 |
| Krzesinski, JM | 1 |
| Hayashi, K | 1 |
| Fukui, T | 3 |
| Richard Hobbs, FD | 1 |
| Gensini, G | 2 |
| John Mancini, GB | 1 |
| Manolis, AJ | 2 |
| Bauer, B | 2 |
| Genest, J | 2 |
| Feldman, RD | 1 |
| Harvey, P | 2 |
| Jenssen, TG | 2 |
| da Silva, PM | 2 |
| Devabhaktuni, M | 1 |
| Thom, S | 1 |
| Stettler, C | 1 |
| Stanton, A | 2 |
| Witt, N | 1 |
| Tapp, R | 1 |
| Chaturvedi, N | 1 |
| Allemann, S | 1 |
| Mayet, J | 1 |
| Hughes, A | 1 |
| Izzo, JL | 2 |
| Nilsson, PM | 1 |
| Liew, D | 1 |
| Park, HJ | 1 |
| Ko, SK | 1 |
| Grothusen, A | 1 |
| Divchev, D | 1 |
| Luchtefeld, M | 1 |
| Schieffer, B | 1 |
| Curran, MP | 1 |
| Sarafidis, PA | 1 |
| Weir, MR | 3 |
| Staikos-Byrne, L | 1 |
| Kelly, RY | 2 |
| Chiang, YT | 1 |
| Zamorano, J | 2 |
| Lopez, AP | 1 |
| Al Khadra, A | 1 |
| Hirata, M | 1 |
| Wang, W | 2 |
| Ma, L | 2 |
| Zhang, Y | 3 |
| Deng, Q | 2 |
| Liu, M | 2 |
| Liu, L | 2 |
| Grimm, R | 1 |
| Malik, M | 1 |
| Kursun, A | 1 |
| Ahrens, K | 1 |
| Bramlage, P | 1 |
| Chapman, RH | 1 |
| Yeaw, J | 1 |
| Roberts, CS | 1 |
| Jamerson, KA | 2 |
| Del Giaccio, A | 1 |
| Eblen-Zajjur, A | 1 |
| Narumi, H | 2 |
| Takano, H | 2 |
| Shindo, S | 2 |
| Fujita, M | 1 |
| Mizuma, H | 2 |
| Komuro, I | 2 |
| Wald, DS | 2 |
| Wald, NJ | 2 |
| Pavia, A | 1 |
| Al-Khadra, A | 1 |
| Sharma, A | 1 |
| Trane, A | 1 |
| Yu, C | 1 |
| Jasmin, JF | 1 |
| Bernatchez, P | 1 |
| Ghiadoni, L | 1 |
| Lins, R | 1 |
| Aerts, A | 1 |
| Coen, N | 1 |
| Hermans, C | 1 |
| MacDonald, K | 1 |
| Brié, H | 1 |
| Lee, C | 1 |
| Shen, YM | 1 |
| Vancayzeele, S | 1 |
| Mecum, N | 1 |
| Abraham, I | 1 |
| Matsuoka, H | 1 |
| Schmidt, M | 1 |
| Johansen, MB | 1 |
| Robertson, DJ | 1 |
| Maeng, M | 1 |
| Kaltoft, A | 1 |
| Jensen, LO | 1 |
| Tilsted, HH | 1 |
| Bøtker, HE | 1 |
| Sørensen, HT | 1 |
| Baron, JA | 1 |
| Hasegawa, H | 1 |
| Kobayashi, Y | 1 |
| Kageyama, S | 1 |
| Ueda, S | 1 |
| Mochizuki, K | 1 |
| Miyakawa, M | 1 |
| Sugawara, M | 1 |
| Nakayama, M | 1 |
| Ohashi, Y | 1 |
| Saito, I | 1 |
| Devereux, RB | 1 |
| Wright, JT | 4 |
| Hua, TA | 2 |
| Hester, RA | 1 |
| Velazquez, E | 1 |
| Zhao, Y | 1 |
| Sun, H | 1 |
| Wang, J | 1 |
| Alderman, MH | 3 |
| Ford, CE | 8 |
| Franklin, SS | 2 |
| Papademetriou, V | 2 |
| Ong, ST | 1 |
| Eckfeldt, JH | 6 |
| Zhang, X | 1 |
| Lynch, AI | 3 |
| Boerwinkle, E | 4 |
| Leiendecker-Foster, C | 3 |
| Arnett, DK | 4 |
| Kim-Mitsuyama, S | 1 |
| Matsui, K | 1 |
| Jinnouchi, T | 1 |
| Jinnouchi, H | 1 |
| Arakawa, K | 1 |
| Irvin, MR | 1 |
| Vaughan, LK | 1 |
| Aissani, B | 1 |
| Shrestha, S | 1 |
| Morris, JK | 1 |
| Proschan, M | 1 |
| Cutler, JA | 2 |
| Graumlich, JF | 1 |
| Pavlik, V | 1 |
| Gordon, D | 1 |
| Blumenthal, SS | 1 |
| Castaldo, RS | 1 |
| Preston, RA | 1 |
| Julius, S | 6 |
| Jia, Y | 1 |
| Brunner, HR | 3 |
| Zappe, DH | 1 |
| Schork, A | 2 |
| Mancia, G | 1 |
| Zanchetti, A | 4 |
| Kereiakes, DJ | 1 |
| Littlejohn, T | 1 |
| Melino, M | 1 |
| Lee, J | 1 |
| Fernandez, V | 1 |
| Heyrman, R | 1 |
| Arslan, Z | 1 |
| Ay, SA | 1 |
| Karaman, M | 1 |
| Cakar, M | 1 |
| Celik, T | 1 |
| Balta, S | 1 |
| Akhan, M | 1 |
| Sarlak, H | 1 |
| Arslan, E | 1 |
| Demirbas, S | 1 |
| Demirkol, S | 1 |
| Bulucu, F | 1 |
| Saglam, K | 1 |
| Zappe, D | 1 |
| Fedacko, J | 1 |
| Pella, D | 1 |
| Jarcuska, P | 1 |
| Sabol, F | 1 |
| Kmec, J | 1 |
| Lopuchovsky, T | 1 |
| Merkovska, L | 1 |
| Jedlickova, L | 1 |
| Janicko, M | 1 |
| Sajty, M | 1 |
| de la Sierra, A | 1 |
| Ostroumova, OD | 1 |
| Nilsson, P | 1 |
| Schmieder, RE | 1 |
| Handrock, R | 1 |
| Berl, T | 1 |
| Hunsicker, LG | 1 |
| Lewis, JB | 1 |
| Pfeffer, MA | 1 |
| Porush, JG | 1 |
| Rouleau, JL | 1 |
| Drury, PL | 1 |
| Esmatjes, E | 1 |
| Hricik, D | 1 |
| Parikh, CR | 1 |
| Raz, I | 1 |
| Vanhille, P | 1 |
| Wiegmann, TB | 1 |
| Wolfe, BM | 1 |
| Locatelli, F | 1 |
| Goldhaber, SZ | 1 |
| Lewis, EJ | 1 |
| Rollins, G | 1 |
| Brunner, H | 1 |
| Hansson, L | 3 |
| Platt, F | 1 |
| Ekman, S | 3 |
| Laragh, JH | 2 |
| McInnes, G | 1 |
| Schork, AM | 1 |
| Smith, B | 3 |
| Weber, M | 2 |
| Felmeden, DC | 1 |
| Blann, AD | 1 |
| Spencer, CG | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Mason, RP | 4 |
| Marche, P | 2 |
| Hintze, TH | 1 |
| Rahn, KH | 1 |
| Hua, T | 2 |
| Laragh, J | 1 |
| Mitchell, L | 2 |
| Plat, F | 2 |
| Schork, MA | 1 |
| Galduf Cabañas, J | 1 |
| Cosín Aguilar, J | 2 |
| Rodríguez-Padialc, L | 1 |
| Zamorano Gómez, JL | 2 |
| Fernández González, I | 1 |
| Rejas Gutiérrrez, J | 1 |
| Frishman, WH | 1 |
| Zuckerman, AL | 1 |
| Berk, BC | 1 |
| Bisognano, JD | 1 |
| Einecke, D | 1 |
| Nissen, SE | 1 |
| Tuzcu, EM | 1 |
| Libby, P | 1 |
| Thompson, PD | 1 |
| Ghali, M | 1 |
| Garza, D | 1 |
| Berman, L | 1 |
| Shi, H | 1 |
| Buebendorf, E | 1 |
| Topol, EJ | 1 |
| Chikamori, T | 1 |
| Tomiyama, H | 1 |
| Yamashina, A | 1 |
| Aboyans, V | 1 |
| Lacroix, P | 1 |
| Cassat, C | 1 |
| Weder, AB | 1 |
| Dunn, JK | 1 |
| Leenen, FH | 2 |
| Margolis, KL | 1 |
| Habib, GB | 1 |
| Jackson, G | 1 |
| Cowie, MR | 1 |
| Miller, MB | 1 |
| Black, H | 1 |
| Hobbs, FD | 2 |
| Mancini, GB | 1 |
| Böhler, S | 1 |
| Feldman, R | 1 |
| Metcalfe, M | 1 |
| Ishikawa, K | 1 |
| Rakugi, H | 1 |
| Bilous, R | 1 |
| Pressel, S | 1 |
| Nwachuku, C | 2 |
| Barzilay, J | 1 |
| Batuman, V | 1 |
| Farber, MA | 1 |
| Franklin, S | 1 |
| Henriquez, M | 1 |
| Kopyt, N | 1 |
| Louis, GT | 1 |
| Saklayen, M | 1 |
| Stanford, C | 1 |
| Walworth, C | 1 |
| Ward, H | 1 |
| Wiegmann, T | 1 |
| Williams, B | 1 |
| Lacy, PS | 1 |
| Thom, SM | 1 |
| Cruickshank, K | 1 |
| Collier, D | 1 |
| Hughes, AD | 1 |
| Thurston, H | 1 |
| O'Rourke, M | 1 |
| van den Meiracker, AH | 1 |
| van Montfrans, GA | 1 |
| Sakamaki, Y | 1 |
| Sasamura, H | 1 |
| Ikeda, S | 1 |
| Ikegami, N | 1 |
| Nwachuku, CE | 1 |
| Simpson, LM | 1 |
| Atlas, SA | 1 |
| Basile, JN | 1 |
| Cuyjet, AB | 1 |
| Dart, R | 1 |
| Felicetta, JV | 1 |
| Grimm, RH | 1 |
| Jafri, SZ | 1 |
| Proschan, MA | 1 |
| Thadani, U | 1 |
| Coleman, JJ | 1 |
| Kendall, MJ | 1 |
| Tedesco, MA | 1 |
| Natale, F | 1 |
| Calabrò, R | 1 |
| Aksnes, TA | 1 |
| Reims, HM | 1 |
| Guptha, S | 1 |
| Moan, A | 1 |
| Os, I | 1 |
| De la Figuera von Wichmann, M | 1 |
| Llisterri Caro, JL | 1 |
| Payeras, AC | 1 |
| Sladek, K | 1 |
| Lembo, G | 1 |
| Alberici, M | 1 |
| Fujita, T | 1 |
| Ando, K | 1 |
| Nishimura, H | 1 |
| Ideura, T | 1 |
| Yasuda, G | 1 |
| Isshiki, M | 1 |
| Takahashi, K | 1 |
| Császár, A | 1 |
| Hernándiz Martínez, A | 1 |
| Masramón Morell, X | 1 |
| Arístegui Urrestarazu, R | 1 |
| Aguilar Llopis, A | 1 |
| Armada Peláez, B | 1 |
| Rodríguez Padial, L | 1 |
| Bönner, G | 1 |
| McKeage, K | 1 |
| Siddiqui, MA | 1 |
| Fukumoto, Y | 1 |
| Yasuda, S | 1 |
| Ito, A | 1 |
| Shimokawa, H | 1 |
| Doggrell, SA | 1 |
| Purcell, H | 1 |
| Clavijo, GA | 1 |
| de Clavijo, IV | 1 |
| Weart, CW | 1 |
| Meyer, C | 1 |
| Haria, M | 1 |
| Wagstaff, AJ | 1 |
| Bobbio, M | 1 |
| Harano, Y | 1 |
| Suzuki, M | 1 |
| Hara, Y | 1 |
| Ryomoto, K | 1 |
| Kanazawa, A | 1 |
| Nishioheda, Y | 1 |
| Tsushima, M | 1 |
| Zamorski, MA | 1 |
| Mann, J | 1 |
| Parving, HH | 1 |
| Witte, K | 1 |
| Schnecko, A | 1 |
| Schmidt, T | 1 |
| Voll, C | 1 |
| Kränzlin, B | 1 |
| Lemmer, B | 1 |
| Shouda, J | 1 |
| Nakamoto, H | 1 |
| Sugahara, S | 1 |
| Okada, H | 1 |
| Suzuki, H | 1 |
| Trumbore, MW | 1 |
| Mason, PE | 1 |
| Williams, CD | 1 |
| Messerli, FH | 1 |
| Studney, D | 1 |
| Opie, LH | 1 |
| Murdoch, D | 1 |
| Heel, RC | 1 |
| Kloner, RA | 1 |
| Przyklenk, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levamlodipine Maleate (Xuanning) or Amlodipine Besylate (Norvasc) for Treatment of Hypertension: A Comparative Effectiveness Research[NCT01844570] | 10,000 participants (Anticipated) | Observational | 2013-02-28 | Active, not recruiting | |||
| The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233] | Phase 4 | 1,150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822] | Phase 4 | 168 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality])[NCT00124969] | Phase 4 | 356 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)[NCT00174304] | Phase 4 | 1,120 participants | Interventional | 2004-10-31 | Completed | ||
| An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)[NCT00330785] | Phase 3 | 1,250 participants | Interventional | 2004-10-31 | Completed | ||
| Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians[NCT01271985] | Phase 3 | 8,410 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice[NCT00407537] | Phase 4 | 1,531 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks[NCT01011660] | Phase 4 | 13,542 participants (Anticipated) | Interventional | 2007-10-31 | Recruiting | ||
| Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk[NCT00134160] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2005-08-31 | Completed | ||
| A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension[NCT00649389] | Phase 3 | 2,500 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Evaluation of a Primary Treatment Algorithm Using Fixed Dose Combination Therapy for the Management of Hypertension - Control and Intervention Arms[NCT00129909] | Phase 4 | 2,081 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT)[NCT02832973] | Phase 4 | 72 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009] | 152 participants (Actual) | Interventional | 2020-03-31 | Completed | |||
| GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901] | 37,939 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease[NCT01932450] | Phase 2 | 100 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)[NCT02584439] | Phase 3 | 30 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Pulse Wave Velocity as a Predictor for Postoperative Cardiovascular Events[NCT03223441] | 543 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Longitudinal Change of Arterial Stiffness Indices in Relation to Ambulatory Aortic and Branchial Pressure in Long Term Peritoneal Dialysis Patients[NCT03607747] | 40 participants (Anticipated) | Observational | 2018-07-18 | Recruiting | |||
| Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)[NCT00237588] | Phase 4 | 25 participants | Interventional | 2004-12-31 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| Improving Hypertension Control in Individuals With Diabetes[NCT00743808] | 11,510 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
(NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Caduet | -10.0128 |
| Usual Care | -6.8429 |
(NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mmHG (Least Squares Mean) |
|---|---|
| Caduet | -8.3024 |
| Usual Care | -6.6908 |
(NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Caduet | -18.2409 |
| Usual Care | -12.4903 |
(NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mmHG (Least Squares Mean) |
|---|---|
| Caduet | -15.3088 |
| Usual Care | -12.1619 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.1 |
| Usual Care | 3.7 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.0 |
| Usual Care | 3.7 |
"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.7 |
| Usual Care | 4.9 |
"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.7 |
| Usual Care | 4.9 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 12.5 |
| Usual Care | 16.3 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 12.5 |
| Usual Care | 16.3 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12
| Intervention | percent risk (Least Squares Mean) | |
|---|---|---|
| Month 4 | Month 12 | |
| Caduet | -1.8438 | -1.9693 |
| Usual Care | -0.9678 | -0.9963 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12
| Intervention | percent risk (Least Squares Mean) | |
|---|---|---|
| Month 4 | Month 12 | |
| Caduet | -7.2705 | -7.2374 |
| Usual Care | -2.5155 | -2.5167 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | -37.1024 | -33.2420 | -0.4339 | -15.2270 |
| Usual Care | -4.0368 | -3.4168 | -1.0105 | 3.0398 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | -42.7542 | -38.2765 | -0.2060 | -20.5645 |
| Usual Care | -3.8144 | -2.9628 | -1.1978 | 3.0828 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 12
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | 163.3 | 87.1 | 47.3 | 151.5 |
| Usual Care | 196.6 | 117.3 | 47.1 | 166.4 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 4
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | 156.0 | 80.9 | 47.6 | 143.5 |
| Usual Care | 195.2 | 116.4 | 46.8 | 164.8 |
(NCT00407537)
Timeframe: Month 12
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Caduet | 130.6 | 79.2 |
| Usual Care | 134.3 | 81.1 |
(NCT00407537)
Timeframe: Month 4
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Caduet | 133.5 | 80.7 |
| Usual Care | 134.5 | 81.1 |
Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Increased dose | increased dose of anti-hypertensive medications | increased dose of lipid lowering medications | increase in either medication | increase in both medications | |
| Caduet | 30 | 30 | 0 | 4 | 0 |
| Usual Care | 90 | 88 | 2 | 45 | 0 |
Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Month 4: anti-hypertensive and/or lipid lowering | Month 4: anti-hypertensive | Month 4: lipid lowering | Month 4: anti-hypertensive and lipid lowering | Month 12: anti-hypertensive and/or lipid lowering | Month 12: anti-hypertensive | Month 12: lipid lowering | Month 12: anti-hypertensive and lipid lowering | |
| Caduet | 648 | 647 | 45 | 44 | 655 | 654 | 46 | 45 |
| Usual Care | 642 | 637 | 202 | 197 | 642 | 638 | 208 | 204 |
Goals set at <140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and <140/90 mm Hg or <130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| JNC Month 4 | JNC Month 12 | ESC Month 4 | ESC Month 12 | |
| Caduet | 65.2 | 76.1 | 48.6 | 58.2 |
| Usual Care | 62.6 | 60.6 | 46.0 | 47.5 |
Goal set at <100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at <80 mg/dL according to the European (EU) Society of Cardiology guidelines. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| US Month 4 | US Month 12 | EU Month 4 | EU Month 12 | |
| Caduet | 77.3 | 71.9 | 52.4 | 46.7 |
| Usual Care | 28.2 | 28.8 | 13.3 | 11.5 |
(NCT00649389)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -17.8 |
| OM40/HCTZ25 | -16.5 |
| AML10/HCTZ25 | -14.8 |
| OM40/AML10/HCTZ25 | -21.5 |
(NCT00649389)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -31.1 |
| OM40/HCTZ25 | -31.2 |
| AML10/HCTZ25 | -28.9 |
| OM40/AML10/HCTZ25 | -38.1 |
(NCT00649389)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| OM40/AML10 | 46.0 |
| OM40/HCTZ25 | 46.6 |
| AML10/HCTZ25 | 34.9 |
| OM40/AML10/HCTZ25 | 64.3 |
(NCT00649389)
Timeframe: Baseline to 12 weeks or early termination
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Diastolic blood pressure | Systolic blood pressure | |
| AML10/HCTZ25 | -10.7 | -18.5 |
| OM40/AML10 | -13.9 | -23.5 |
| OM40/AML10/HCTZ25 | -18.0 | -30.3 |
| OM40/HCTZ25 | -14.5 | -23.9 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 10 |
| Continuation Arm | 11 |
"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | units on a scale (SOFA x days) (Median) |
|---|---|
| Discontinuation Arm | 7 |
| Continuation Arm | 12 |
"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | score on a scale (range 1 to 152) (Median) |
|---|---|
| Discontinuation Arm | 81 |
| Continuation Arm | 73 |
Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 8 |
| Continuation Arm | 9 |
Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 14 |
| Continuation Arm | 16 |
This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 5 |
| Continuation Arm | 6 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 15 |
| Continuation Arm | 13 |
41 reviews available for amlodipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Reconsidering the Polypill for Management of Cardiovascular Risk Factors in Underserved Patients.
Topics: Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Heart Disease Risk | 2021 |
[Lipertance® The ASCOT single-pill combination has finally arrived].
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Huma | 2017 |
Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD.
Topics: Age Factors; Amlodipine; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; | 2013 |
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalido | 2014 |
Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2015 |
Rationale for a single-pill combination of perindopril arginine and amlodipine besylate.
Topics: Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combina | 2015 |
Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blocker | 2016 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvast | 2008 |
Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2008 |
[The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2009 |
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases | 2009 |
Hypertension and diabetes: should we treat early surrogates? What are the cons?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseas | 2009 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2009 |
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseas | 2010 |
Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2010 |
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseas | 2010 |
Perindopril for the treatment of hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardi | 2011 |
Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cardiovascular Diseases; Ca | 2003 |
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topi | 2004 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases | 2005 |
[Recent multi-center clinical studies about calcium blockade and cardiovascular diseases].
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2006 |
Will ASCOT change the form of anti-hypertensive therapy?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2006 |
The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2006 |
[CASE-J].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
[Overview of cardiovascular risk factors].
Topics: Age Factors; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; As | 2006 |
Vascular pleiosynergy--does it really work?
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Drug Synergism; Endothelium, | 2007 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Guidelines as Topic; H | 2007 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Disease | 2008 |
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; Evid | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Tr | 2006 |
[Present and future possibilities in the use of calcium antagonists in the therapy of cardiovascular diseases with special emphasis on amlodipine].
Topics: Amlodipine; Cardiovascular Diseases; Humans | 1994 |
Amlodipine: a new calcium antagonist.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Humans | 1994 |
Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.
Topics: Amlodipine; Angina Pectoris; Cardiovascular Diseases; Hemodynamics; Humans; Hypertension | 1995 |
Calcium antagonists and cardiovascular risk in diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Cli | 1999 |
[Amlodipine and the mechanisms of vascular hypertrophy].
Topics: Amlodipine; Calcium Channel Blockers; Calcium Channels; Cardiovascular Diseases; Cell Division; Huma | 2000 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Profiles of calcium antagonists in cardiovascular disease with special reference to second-generation agents and amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Binding Sites; Calcium Channel Blockers; Calcium Channels; Card | 1991 |
Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine | 1991 |
Progress in cardioprotection: the role of calcium antagonists.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Dogs; Humans; Nifedipine | 1990 |
68 trials available for amlodipine and Cardiovascular Diseases
83 other studies available for amlodipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chlorthalid | 2021 |
An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention.
Topics: Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Expert Testimony; H | 2023 |
Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Fem | 2023 |
Importance of fixed-dose combinations in cardiovascular prevention: the possibility of treating two diagnoses with a single pill.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Com | 2020 |
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly A | 2020 |
The gingival crevicular fluid levels of growth factors in patients with amlodipine-induced gingival overgrowth: A pilot study.
Topics: Amlodipine; Cardiovascular Agents; Cardiovascular Diseases; Gingival Crevicular Fluid; Gingival Over | 2020 |
Effect of Methylene Blue on a Porcine Model of Amlodipine Toxicity.
Topics: Amlodipine; Animals; Antidotes; Cardiotoxicity; Cardiovascular Diseases; Cardiovascular System; Dise | 2020 |
The particulars of certain drugs' effect on the endogenous coenzyme Q10 plasma level in patients with cardiovascular diseases.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Female; Hum | 2020 |
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management].
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Com | 2021 |
Combination cardiovascular drugs.
Topics: Aminobutyrates; Amlodipine; Aspirin; Biphenyl Compounds; Cardiovascular Agents; Cardiovascular Disea | 2017 |
[Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Hum | 2017 |
Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardi | 2018 |
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiov | 2018 |
'Temporary Plasticiser': A novel solution to fabricate 3D printed patient-centred cardiovascular 'Polypill' architectures.
Topics: Amlodipine; Cardiovascular Agents; Cardiovascular Diseases; Chemistry, Pharmaceutical; Crystallizati | 2019 |
Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Choleste | 2013 |
Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
Topics: Amlodipine; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combin | 2013 |
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascu | 2014 |
Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin Receptor Antagonists; Antihype | 2015 |
Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cardiovascu | 2016 |
Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real-world' retrospective cohort study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Databases, Factual; Drug Substit | 2016 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Com | 2017 |
[Unexpected study data for treatment of hypertension. Combination therapy with a diuretic not imperative].
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Cardiovascular Diseases; Cause of Death; Drug Com | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumeth | 2008 |
Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Press | 2009 |
Does it matter how hypertension is controlled?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2008 |
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial.
Topics: Adrenergic Antagonists; Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calciu | 2009 |
Diabetes and hypertension: which is the best approach?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2009 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Ch | 2009 |
[Clinical study of the month. The ACCOMPLISH study: challenging the choice of antihypertensive medications in systolic hypertensive patients with high cardiovascular risk].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Cardiov | 2009 |
Lessons from the ACCOMPLISH trial.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Cardiovascular Diseases; Drug Therapy, Combinatio | 2009 |
Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Co | 2009 |
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort | 2010 |
Strengthening diuretics' role in hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2010 |
Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Bendroflumethiazide; Cardiovasc | 2012 |
The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes | 2011 |
Amlodipine increases endothelial nitric oxide release by modulating binding of native eNOS protein complex to caveolin-1.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Cattle; Caveolin 1; Chloroce | 2011 |
Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study).
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; C | 2011 |
Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angioplasty, Balloon, Coronary; Calcium Chan | 2012 |
RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2013 |
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Topics: Amlodipine; Antihypertensive Agents; Biostatistics; Blood Pressure; Cardiovascular Diseases; Chlorth | 2013 |
Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardio | 2013 |
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Calciu | 2002 |
[ALLHAT--the most comprehensive antihypertensive treatment trial in the world. The significance of thiazide diuretics for patients older than 55 years is confirmed].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazin | 2003 |
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
Diuretics are better first-line antihypertensive therapy than calcium channel blockers and ACE inhibitors.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2003 |
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2004 |
[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cardiovascular Diseas | 2004 |
VALUE in hypertension treatment.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Disease | 2004 |
[AT1 blocker or calcium antagonist in treatment of hypertension. What protects the heart better?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Top | 2004 |
[VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2004 |
[VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks].
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel | 2004 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure.
Topics: Amlodipine; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calc | 2005 |
Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2005 |
The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Cardiovascular Diseases; Drug Therapy, Combinatio | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Blood pressure and cardiovascular risk reduction--new targets, new challenges.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Enalapril; Humans; Hyp | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
24-hour protection and control: a new era of calcium antagonists. Proceedings of a satellite symposium, Cannes, France, September 15, 1989.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Humans | 1991 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiov | 2006 |
A rationale for combination therapy in risk factor management: a mechanistic perspective.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Disease Management; Drug Therapy, Combination; En | 2005 |
[ASCOT Study of optimal hypertension therapy. New study results against the "diuretics first" recommendation].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseas | 2005 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
[The most recent study into blood pressure lowering by amlodipine: the beginning of the end for the beta-blockers].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Dis | 2006 |
Results of the ASCOT-BPLA trial: no practical implications for treatment of hypertension.
Topics: Amlodipine; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; | 2006 |
Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Disea | 2006 |
Atorvastatin + amlodipine: new drug. Just a commercial ploy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascu | 2007 |
[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study].
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers | 2007 |
[Hypertension therapy for type 2 diabetics].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2007 |
[Risk oriented therapy of hypertension. Lowering blood pressure and risk].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardio | 2007 |
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiovascular | 2008 |
Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlodipine.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cardiovascula | 2008 |
New drugs in the cardiovascular arena.
Topics: Amlodipine; Bisoprolol; Cardiovascular Agents; Cardiovascular Diseases; Humans; Quinolines; Sotalol; | 1993 |
Amlodipine in chronic heart failure.
Topics: Amlodipine; Calcium Channel Blockers; Cardiovascular Diseases; Data Interpretation, Statistical; Hum | 1997 |
Clinical impact of insulin resistance syndrome in cardiovascular diseases and its therapeutic approach.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blo | 1996 |
Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR(mREN2)27 rats.
Topics: Albumins; Amlodipine; Animals; Animals, Genetically Modified; Blood Pressure; Calcium; Calcium Chann | 1999 |
Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Cardiovascular Diseases; Felodipine; Female; Gingival H | 1999 |
[Membrane biophysical interaction of amlodipine and antioxidant properties].
Topics: Amlodipine; Animals; Antioxidants; Binding Sites; Biophysical Phenomena; Biophysics; Calcium Channel | 2000 |
Costs and outcomes of switching from amlodipine to felodipine.
Topics: Amlodipine; Calcium Channel Blockers; Cardiovascular Diseases; Felodipine; Humans; Treatment Outcome | 2000 |
Confusing Press Releases and the PREVENT Study.
Topics: Amlodipine; Calcium Channel Blockers; Cardiovascular Diseases; Congresses as Topic; Coronary Vessels | 2001 |
Amlodipine in cardiovascular disease: the need for 24-hour protection and control. Proceedings of a meeting, Hong Kong, February 17, 1990.
Topics: Amlodipine; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine | 1991 |
Calcium antagonists in cardiovascular disease: rationale for 24-hour action. Proceedings of an official satellite symposium and papers on amlodipine presented at the 25th Anniversary International Symposium on Calcium Antagonists in Hypertension. Basel, S
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nifedipine | 1988 |